1Socinski MA,Novello S,Brahmer JR,et al.Multicenter,phase Ⅱ trial of sunitinib in previously treated,advanced non-small-cell lung cancer[J].J Clin Onco1,2008,26(4):650-6.
2Novello S,Seagliotti GV,Rosell R,et al.Phase Ⅱ study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer[J].BrJ Cancer,2009,101(9):1543-8.
3Tassi R,Muto A,Rangan S,et al.Response and safety of sunitinib in a heavily pre-treated metastatic non-mall cell lung carcinoma patient[J].Anticancer Res,2010,30(12):5169-73.
4Adams VR,Leggas M.Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors[J].Clin Ther,2007,29(7):1338-53.
5Cabebe E, Wakelee H. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol, 2007, 8 : 15-27.
6Mancuso P, Burlini A, Pruneri G, et al. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood, 2001,97:3658-3661.
7Mouroux J, Padovani B, Elkaim D, et al. Should cavitated bronchopulmonary cancers be considered a separate entity? Ann Thorac Surg, 1996, 61:530-532.
8Cohen MH, Gootenberg J, Keegan P, et al. FDA drug approval summary : bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist, 2007, 12:713-718.
9Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase Ⅱ trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol, 2004, 22:2184-2191.
10Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med, 1971, 255:1182-1186.
